
    
      The drug being tested in this study is called cabozantinib tablets. This tablet is being
      tested to treat people who have radically unresectable or metastatic renal cell carcinoma.

      This study is an observational (non-interventional) study and will look at occurrence of
      adverse drug reactions (or adverse events) of cabozantinib tablets in the routine clinical
      setting. The planned number of observed patients will be approximately 300.

      This multi-center observational trial will be conducted in Japan.
    
  